NASDAQ:NTLA Intellia Therapeutics (NTLA) Stock Price, News & Analysis $12.47 -0.76 (-5.74%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$12.39 -0.08 (-0.62%) As of 10/30/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Intellia Therapeutics Stock (NASDAQ:NTLA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Intellia Therapeutics alerts:Sign Up Key Stats Today's Range$12.04▼$13.1650-Day Range$11.16▼$13.5152-Week Range$7.95▼$18.48Volume4.08 million shsAverage Volume5.51 million shsMarket Capitalization$1.75 billionP/E RatioN/ADividend YieldN/APrice Target$20.57Consensus RatingHold Company Overview Intellia Therapeutics, Inc. is a biotechnology company focused on developing potentially curative treatments using CRISPR-based gene-editing technology. The company is working to create therapies that can modify disease-causing genes inside the body, with the goal of addressing the underlying causes of serious genetic diseases rather than treating only their symptoms. Intellia’s pipeline has included NTLA-2001, an investigational in vivo gene-editing therapy designed to reduce production of transthyretin for the treatment of transthyretin amyloidosis, and NTLA-2002, an investigational therapy intended to target hereditary angioedema. The company has also pursued additional gene-editing programs for genetic and immune-related conditions, including through research and development collaborations. Founded in 2014 and headquartered in Cambridge, Massachusetts, Intellia has built its platform around CRISPR/Cas9 editing delivered directly to patients as well as edited-cell approaches. The company has collaborated with Regeneron Pharmaceuticals on the discovery and development of in vivo gene-editing medicines. Intellia is led by John M. Leonard, Ph.D., who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Intellia Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreNTLA MarketRank™: 2.97622141372 of 5 starsIntellia Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 407th out of 896 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingIntellia Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 1 strong buy rating, 9 buy ratings, 7 hold ratings, and 5 sell ratings.Upside PotentialIntellia Therapeutics has a consensus price target of $20.57, representing about 65.0% upside from its current price of $12.47.Amount of Analyst CoverageIntellia Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Intellia Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Intellia Therapeutics are expected to grow in the coming year, from ($3.21) to ($2.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intellia Therapeutics is -3.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intellia Therapeutics is -3.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntellia Therapeutics has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Intellia Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted32.86% of the float of Intellia Therapeutics has been sold short.Short Interest Ratio / Days to CoverIntellia Therapeutics has a short interest ratio ("days to cover") of 6.45.Change versus previous monthShort interest in Intellia Therapeutics has recently decreased by 1.50%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIntellia Therapeutics does not currently pay a dividend.Dividend GrowthIntellia Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.32 News SentimentIntellia Therapeutics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Intellia Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 16 people have searched for NTLA on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.MarketBeat Follows7 people have added Intellia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Intellia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,170.00 in company stock.Percentage Held by Insiders3.50% of the stock of Intellia Therapeutics is held by insiders.Percentage Held by Institutions88.77% of the stock of Intellia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Intellia Therapeutics' insider trading history. Receive NTLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NTLA Stock News HeadlinesIntellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026October 29 at 8:00 AM | globenewswire.comIntellia Therapeutics (NTLA) Projected to Announce Earnings on ThursdayOctober 29 at 3:26 AM | americanbankingnews.comYour free stock pick for todayElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.October 31 at 1:00 AM | Behind the Markets (Ad)Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 28 at 4:15 PM | globenewswire.comIntellia Therapeutics (NASDAQ:NTLA) vs. Spyre Therapeutics (NASDAQ:SYRE) Head to Head ContrastOctober 23, 2026 | americanbankingnews.comIntellia Therapeutics, Inc. (NTLA) - What Are Researchers Thinking About This Stock?October 22, 2026 | americanbankingnews.comIntellia Therapeutics (NTLA) Stock Looks Overvalued As Launch Preparations AdvanceOctober 19, 2026 | finance.yahoo.comIntellia Therapeutics (NASDAQ:NTLA) Stock: Insider Michael Dube Sells 1,864 SharesOctober 7, 2026 | insidertrades.comSee More Headlines NTLA Stock Analysis - Frequently Asked Questions How have NTLA shares performed this year? Intellia Therapeutics' stock was trading at $8.99 on January 1st, 2026. Since then, NTLA stock has increased by 38.7% and is now trading at $12.47. How were Intellia Therapeutics' earnings last quarter? Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced its quarterly earnings results on Thursday, August, 6th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by $0.00. Intellia Therapeutics's revenue for the quarter was down 46.4% compared to the same quarter last year. Read the conference call transcript. When did Intellia Therapeutics IPO? Intellia Therapeutics (NTLA) raised $102 million in an IPO on Friday, May 6th 2016. The company issued 6,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Intellia Therapeutics' major shareholders? Top institutional investors of Intellia Therapeutics include Sumitomo Mitsui Trust Group Inc. (2.57%), Pinnacle Associates Ltd. (0.26%), Assenagon Asset Management S.A. (0.23%) and Oppenheimer & Co. Inc. (0.08%). Insiders that own company stock include John M Leonard, Edward J Dulac III, William J Chase, James Basta, Birgit C Schultes, Eliana Clark, Michael P Dube, David Lebwohl, Laura Sepp-Lorenzino, Glenn Goddard and Jesse Goodman. View institutional ownership trends. How do I buy shares of Intellia Therapeutics? Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Intellia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intellia Therapeutics investors own include CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU) and Block (XYZ). Company Calendar Last Earnings8/06/2026Today10/31/2026Next Earnings (Estimated)11/05/2026Study update11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 NTLA's financial health is in the Green zone, according to TradeSmith. NTLA has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NTLA CIK1652130 Webwww.intelliatx.com Phone(857) 285-6200FaxN/AEmployees377Year Founded2014Price Target and Rating Average Price Target for Intellia Therapeutics$20.57 High Price Target$49.00 Low Price Target$5.00 Potential Upside/Downside+65.0%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)($3.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$412.69 million Net Margins-672.16% Pretax Margin-672.16% Return on Equity-57.79% Return on Assets-47.29% Debt Debt-to-Equity RatioN/A Current Ratio6.65 Quick Ratio6.65 Sales & Book Value Annual Sales$67.67 million Price / Sales25.82 Cash FlowN/A Price / Cash FlowN/A Book Value$5.80 per share Price / Book2.15Miscellaneous Outstanding Shares140,130,000Free Float135,223,000Market Cap$1.75 billion OptionableOptionable Beta1.80 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:NTLA) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour free stock pick for todayElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredWhat Elon Musk's Cybercab Reveal Could Mean for InvestorsJeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
